Cargando…

Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations

BACKGROUND: The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikasi, Sello Given, Isaacs, Darren, Chitongo, Rumbidzai, Ikomey, George Mondide, Jacobs, Graeme Brendon, Cloete, Ruben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063366/
https://www.ncbi.nlm.nih.gov/pubmed/33892628
http://dx.doi.org/10.1186/s12879-021-06059-x
_version_ 1783681940365246464
author Mikasi, Sello Given
Isaacs, Darren
Chitongo, Rumbidzai
Ikomey, George Mondide
Jacobs, Graeme Brendon
Cloete, Ruben
author_facet Mikasi, Sello Given
Isaacs, Darren
Chitongo, Rumbidzai
Ikomey, George Mondide
Jacobs, Graeme Brendon
Cloete, Ruben
author_sort Mikasi, Sello Given
collection PubMed
description BACKGROUND: The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens. METHODS: We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistance-associated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations was addressed within the context of a 3D model of the HIV-1 IN complex and interaction analysis was performed using PyMol to validate DTG binding to the Wild type and seven mutant structures. RESULTS: We observed 12.8% (37/287) sequences to contain RAMs, with only 1.0% (3/287) of the sequences having major INSTI RAMs: T66A, Q148H, R263K and N155H. Of these,11.8% (34/287) of the sequences contained five different IN accessory mutations; namely Q95K, T97A, G149A, E157Q and D232N. NOPs occurred at a frequency of 66% on the central core domain (CCD) position, 44% on the C-terminal domain (CTD) position and 35% of the N-terminal domain (NTD) position. The interaction analysis revealed that DTG bound to DNA, 2MG ions and DDE motif residues for T66A, T97A, Q148H, N155H and R263K comparable to the WT structure. Except for accessory mutant structure E157Q, only one MG contact was made with DTG, while DTG had no MG ion contacts and no DDE motif residue contacts for structure D232N. CONCLUSIONS: Our analysis indicated that all RAM’s that resulted in a change in the number of interactions with encompassing residues does not affect DTG binding, while accessory mutations E157Q and D232N could affect DTG binding leading to possible DTG resistance. However, further experimental validation is required to validate the in silico findings of our study.
format Online
Article
Text
id pubmed-8063366
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80633662021-04-23 Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations Mikasi, Sello Given Isaacs, Darren Chitongo, Rumbidzai Ikomey, George Mondide Jacobs, Graeme Brendon Cloete, Ruben BMC Infect Dis Research Article BACKGROUND: The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens. METHODS: We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistance-associated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations was addressed within the context of a 3D model of the HIV-1 IN complex and interaction analysis was performed using PyMol to validate DTG binding to the Wild type and seven mutant structures. RESULTS: We observed 12.8% (37/287) sequences to contain RAMs, with only 1.0% (3/287) of the sequences having major INSTI RAMs: T66A, Q148H, R263K and N155H. Of these,11.8% (34/287) of the sequences contained five different IN accessory mutations; namely Q95K, T97A, G149A, E157Q and D232N. NOPs occurred at a frequency of 66% on the central core domain (CCD) position, 44% on the C-terminal domain (CTD) position and 35% of the N-terminal domain (NTD) position. The interaction analysis revealed that DTG bound to DNA, 2MG ions and DDE motif residues for T66A, T97A, Q148H, N155H and R263K comparable to the WT structure. Except for accessory mutant structure E157Q, only one MG contact was made with DTG, while DTG had no MG ion contacts and no DDE motif residue contacts for structure D232N. CONCLUSIONS: Our analysis indicated that all RAM’s that resulted in a change in the number of interactions with encompassing residues does not affect DTG binding, while accessory mutations E157Q and D232N could affect DTG binding leading to possible DTG resistance. However, further experimental validation is required to validate the in silico findings of our study. BioMed Central 2021-04-23 /pmc/articles/PMC8063366/ /pubmed/33892628 http://dx.doi.org/10.1186/s12879-021-06059-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Mikasi, Sello Given
Isaacs, Darren
Chitongo, Rumbidzai
Ikomey, George Mondide
Jacobs, Graeme Brendon
Cloete, Ruben
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
title Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
title_full Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
title_fullStr Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
title_full_unstemmed Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
title_short Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
title_sort interaction analysis of statistically enriched mutations identified in cameroon recombinant subtype crf02_ag that can influence the development of dolutegravir drug resistance mutations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063366/
https://www.ncbi.nlm.nih.gov/pubmed/33892628
http://dx.doi.org/10.1186/s12879-021-06059-x
work_keys_str_mv AT mikasisellogiven interactionanalysisofstatisticallyenrichedmutationsidentifiedincameroonrecombinantsubtypecrf02agthatcaninfluencethedevelopmentofdolutegravirdrugresistancemutations
AT isaacsdarren interactionanalysisofstatisticallyenrichedmutationsidentifiedincameroonrecombinantsubtypecrf02agthatcaninfluencethedevelopmentofdolutegravirdrugresistancemutations
AT chitongorumbidzai interactionanalysisofstatisticallyenrichedmutationsidentifiedincameroonrecombinantsubtypecrf02agthatcaninfluencethedevelopmentofdolutegravirdrugresistancemutations
AT ikomeygeorgemondide interactionanalysisofstatisticallyenrichedmutationsidentifiedincameroonrecombinantsubtypecrf02agthatcaninfluencethedevelopmentofdolutegravirdrugresistancemutations
AT jacobsgraemebrendon interactionanalysisofstatisticallyenrichedmutationsidentifiedincameroonrecombinantsubtypecrf02agthatcaninfluencethedevelopmentofdolutegravirdrugresistancemutations
AT cloeteruben interactionanalysisofstatisticallyenrichedmutationsidentifiedincameroonrecombinantsubtypecrf02agthatcaninfluencethedevelopmentofdolutegravirdrugresistancemutations